The impact of PET on the management of lung cancer: the referring physician's perspective.

UNLABELLED (18)F-FDG PET is a molecular whole-body imaging modality that is increasingly being used for diagnosing, staging, and restaging cancer. The objective of this study was to determine referring physicians' perspectives on the impact of (18)F-FDG PET on staging and management of lung cancer. METHODS A questionnaire was sent to the 292 referring physicians of 744 consecutive patients with known or suspected lung cancer who were evaluated with PET. Questionnaires on 274 patients were returned (response rate, 37%). Management changes were categorized as intermodality (e.g., surgery to medical, surgery to radiation, and medical to no treatment) or intramodality (e.g., altered medical, surgical, or radiotherapy approach). RESULTS The primary reasons for PET referral were staging of lung cancer in 61% of patients, diagnosis in 20%, and monitoring of therapy or the course of disease in 6%. Physicians reported that PET caused them to change their decision on clinical stage in 44% of all patients: The disease was upstaged in 29% and downstaged in 15%. PET resulted in intermodality management changes in 39% of patients, whereas 15% had an intramodality change. CONCLUSION This survey-based study of referring physicians suggests that PET has a major impact on staging and management of lung cancer.

[1]  Richard M. Leahy,et al.  A theoretical study of the contrast recovery and variance of MAP reconstructions from PET data , 1999, IEEE Transactions on Medical Imaging.

[2]  H. Lodish,et al.  Elevated levels of glucose transport and transporter messenger RNA are induced by ras or src oncogenes. , 1987, Science.

[3]  G. Weber.  Enzymology of cancer cells (first of two parts). , 1977, The New England journal of medicine.

[4]  A. Cartwright.  Professionals as responders: variations in and effects of response rates to questionnaires, 1961-77. , 1978, British medical journal.

[5]  H. Morris,et al.  Comparative biochemistry of hepatomas. I. Carbohydrate enzymes in Morris hepatoma 5123. , 1961, Cancer research.

[6]  C. Mountain,et al.  Revisions in the International System for Staging Lung Cancer. , 1997, Chest.

[7]  Scott T. Grafton,et al.  PET and [18F]-FDG in oncology: a clinical update. , 1996, Nuclear medicine and biology.

[8]  V Kalff,et al.  Clinical impact of (18)F fluorodeoxyglucose positron emission tomography in patients with non-small-cell lung cancer: a prospective study. , 2001, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[9]  C. Borror.  Practical Nonparametric Statistics, 3rd Ed. , 2001 .

[10]  M E Phelps,et al.  Whole-body positron emission tomography: Part I. Methods and performance characteristics. , 1992, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[11]  H. Wagner.  The incremental value of diagnostic tests. , 1997, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[12]  J. Bradshaw,et al.  Physician Participation in Research Surveys , 1999, Evaluation & the health professions.

[13]  H. Groen,et al.  Preoperative staging of non-small-cell lung cancer with positron-emission tomography. , 2000, The New England journal of medicine.

[14]  A. Hogg,et al.  High rate of detection of unsuspected distant metastases by pet in apparent stage III non-small-cell lung cancer: implications for radical radiation therapy. , 2001, International journal of radiation oncology, biology, physics.

[15]  P. Valk,et al.  Cost-effectiveness of PET imaging in clinical oncology. , 1996, Nuclear medicine and biology.

[16]  S S Gambhir,et al.  A tabulated summary of the FDG PET literature. , 2001, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[17]  W. J. Conover,et al.  Practical Nonparametric Statistics , 1972 .

[18]  R. A. Groeneveld,et al.  Practical Nonparametric Statistics (2nd ed). , 1981 .

[19]  R. Coleman,et al.  PET in lung cancer. , 1999, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[20]  S S Gambhir,et al.  Decision tree sensitivity analysis for cost-effectiveness of FDG-PET in the staging and management of non-small-cell lung carcinoma. , 1997, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[21]  R L Wahl,et al.  Metastases from non-small cell lung cancer: mediastinal staging in the 1990s--meta-analytic comparison of PET and CT. , 1999, Radiology.

[22]  S S Gambhir,et al.  PET in oncology: will it replace the other modalities? , 1997, Seminars in nuclear medicine.

[23]  M. O'Doherty,et al.  Evaluation of fluorine-18-fluorodeoxyglucose whole body positron emission tomography imaging in the staging of lung cancer. , 1999, The Annals of thoracic surgery.

[24]  S S Gambhir,et al.  Impact of whole-body 18F-FDG PET on staging and managing patients with breast cancer: the referring physician's perspective. , 2001, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[25]  Wahl Rl.  PET begins to prove itself in cancer care. , 1996 .

[26]  Gary T. Smith,et al.  Cost Analysis of FDG PET for Managing Patients with Ovarian Cancer. , 1999, Clinical positron imaging : official journal of the Institute for Clinical P.E.T.

[27]  P. Valk,et al.  Impact of 18F-FDG PET on managing patients with colorectal cancer: the referring physician's perspective. , 2001, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[28]  W. J. Lorenz,et al.  Performance evaluation of the whole-body PET scanner ECAT EXACT HR + , 1997 .

[29]  Michael E. Phelps,et al.  Effect of Whole-Body 18F-FDG PET Imaging on Clinical Staging and Management of Patients with Malignant Lymphoma , 2001 .

[30]  Maximising response rates in a survey of general practitioners. Lessons from a Victorian survey on sexually transmissible diseases. , 1998, Australian family physician.

[31]  B F Hutton,et al.  Accelerated EM reconstruction in total-body PET: potential for improving tumour detectability. , 1994, Physics in medicine and biology.

[32]  V Kalff,et al.  F‐18 fluorodeoxyglucose positron emission tomography staging in radical radiotherapy candidates with nonsmall cell lung carcinoma , 2001, Cancer.